Skip to content
Open access

A detoxified E. coli heat-labile toxin LTh(αK) as a mucosal immunomodulator against acute respiratory viral infection: Proof-of-concept in a SARS-CoV-2 rodent model.

Sep 2026 · Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 0 citations · 25 references
Medicine

Abstract

Background

Acute respiratory viral infections remain a global health burden, and current vaccines induce limited mucosal immunity at the respiratory epithelium. Host-directed strategies that strengthen innate mucosal responses may offer broader protection. LTh(αK), a genetically detoxified E. coli heat-labile toxin with established adjuvant safety, was evaluated for its capacity to enhance mucosal immunity and mitigate respiratory viral injury, using SARS-CoV-2 as a representative challenge model.

Methods

LTh(αK) was tested as a mucosal vaccine adjuvant and as a host-directed immunotherapy. C57BL/6 mice received an intranasal LTh(αK)-adjuvanted SARS-CoV-2 spike protein (S2P) vaccine; serum IgG and IgA and Th1/Th2 cytokines were measured. Syrian golden hamsters received intranasal LTh(αK) after viral challenge, with assessment of clinical parameters, viral titers, histopathology and cytokine transcription.

Results

As an adjuvant, LTh(αK) increased S-specific serum IgG and IgA and Th1 and Th2 cytokine levels. As immunotherapy, LTh(αK) attenuated infection symptoms but did not significantly reduce virus titers at any site or time point, while significantly increasing interferon-beta (IFNβ) transcription in the cranial lung lobe. Overall histopathological lesion scores were significantly lower in LTh(αK)-treated animals at 3 days post-challenge (dpc), a difference not sustained at 5 or 7 dpc. Ultrastructural examination additionally showed increased monocyte activation and reduced mucin production, hemorrhage and lung parenchyma destruction.

Conclusion

LTh(αK) enhanced Th1/Th2 balanced humoral immunity, including S-specific serum IgA, and attenuated early lung injury without reducing viral burden. These proof-of-concept findings support LTh(αK) as a candidate host-directed mucosal immunomodulator for acute respiratory viral infections and warrant further evaluation of its translational potential.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.